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Background: Recent investigations suggest that neutrophils play an important role in the immune response to
lung cancer as well as chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate the
amount of neutrophils and markers of their activity in lung cancer and COPD and in coexistence of these two
diseases.
Methods: In total, 267 persons were included in the study: 139 patients with lung cancer, 55 patients with lung
cancer and COPD, 40 patients with COPD, and 33 healthy subjects. Peripheral blood and BAL fluid samples were
obtained for cell count analysis and determination of NE, MPO levels and ROS production. NE and MPO levels in
the serum and BAL fluid were determined by ELISA. ROS production was analyzed by flow cytometer.
Results: The percentage, cell count of neutrophils and neutrophil to lymphocyte ratio in the peripheral blood were
significantly higher in lung cancer patients with or without COPD compared to COPD patients or healthy
individuals (P < 0.05). The percentage and cell count of neutrophils in BAL fluid were significantly lower in patients
with lung cancer with or without COPD than in patients with COPD (P < 0.05). However, BAL fluid and serum levels
of both NE and MPO were significantly higher in patients with lung cancer than COPD patients or healthy
individuals (P < 0.05). Neutrophils produced higher amounts of ROS in patients with lung cancer with or without
COPD compared with COPD patients or healthy individuals (P < 0.05).
Conclusions: The results from this study demonstrate higher degree of local and systemic neutrophilic
inflammation in patients with lung cancer (with or without COPD) than in patients with COPD.
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Cancer is a multifactorial disease which is determined by
complex interactions between genetic variants and envi-
ronmental factors [1]. Various non-infectious chronic in-
flammatory conditions have been consistently associated
with the increased risk of cancer development. Examples
would be large bowel inflammatory conditions, which
create a risk of colorectal cancer, chronic pancreatitis,
which may precede the development of pancreatic cancer,
and chronic obstructive pulmonary disease (COPD),
which increases the risk of lung cancer [2]. However, there* Correspondence: neringa.vaguliene@gmail.com
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reproduction in any medium, provided the orare many unanswered questions about the role of chronic
inflammation in cancer development [2]. COPD, as well
as lung cancer, are disorders characterized by an abnormal
local and systemic inflammatory response with smoking
as a major environmental risk factor [3].
Chronic inflammation involves activation and recruit-
ment of leucocytes, especially neutrophils. Neutrophils are
key blood cells, which respond immediately to inflamma-
tory stimulus and contain a wide range of toxic com-
pounds for pathogen removal [3]. Furthermore, the release
of huge amounts of reactive oxygen species (ROS) by neu-
trophils plays a key role in enhancing the inflammation
through the activation of mitogen-activated protein kinases
and redox-sensitive transcription factors such as nuclear
factor kappa B and activator protein-1 [4]. A small amountral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tosis. However, high amounts of ROS may act as car-
cinogenic agents by inducing structural changes in DNA
and by modulating stress gene expression [5]. An oxidative
stress is known to be increased in the cells of lung cancer
patients and COPD patients, especially smokers [6-8].
Activated neutrophils express serine proteases, including
neutrophil elastase (NE), cathepsin G, and proteinase-3,
matrix metalloproteinases (MMP)-8, MMP-9, and pro-
teins, such as myeloperoxidase (MPO) and human neutro-
phil lipocalin, and release them from the granules into the
extracellular space. These mediators play an important
role in the inflammatory process [9,10]. Neutrophil elas-
tase is a neutral protease that is able to degrade insoluble
elastin. The imbalance between proteases and their inhi-
bitors (alpha 1-antitrypsin) may cause emphysematous
changes in the lung tissue and the development of COPD.
Furthermore, NE has also been shown to cleave cell
surface epidermal growth factor and transfor growth
factor-alpha [11]. The role of NE in the development of
lung cancer has been described in animal models and
cell-line studies [12,13], but there is limited data from the
investigations of lung cancer patients. Myeloperoxidase is
an endogenous oxidant enzyme, which plays an important
role in bacterial killing by neutrophils and is involved in
COPD pathogenesis [14]. In addition, there is evidence of
MPO role in pathogenesis of lung cancer [15]. Neutrophil
elastase and MPO are mostly released from activated
neutrophils and act locally in the airways and other
pulmonary compartments. However, these inflammatoryTable 1 Characteristics of subjects
Variable
Lung cancer gro




Age, mean ± SEM, years 63.1 ± 0.9
BMI, mean ± SEM, kg/m2 27.3 ± 0.4
Smoking historyaa
Never smoker 30 (21.6)
Former smoker 27 (19.4)
Current smoker 82 (59.0)
Smoking pack-years, median (range):
Former smoker 28.0 (10–54)
Current smoker 38.0 (10–60)
FEV1, mean ± SEM, % pred 91.2 ± 1.7*
FEV1/FVC ratio, mean ± SEM, % pred 96.6 ± 0.7*
FEV1 forced expiratory volume in one second, FVC forced vital capacity, BMI body m
*P < 0.05, when compared to lung cancer with COPD, COPD, and healthy individual
§P < 0.05, when compared with healthy individuals.
aχ2-10.61, P < 0.05.
aaχ2-48.14, P < 0.001.mediators can be also detected in serum and be consi-
dered as parameters of systemic inflammation [10,14].
Local inflammation, the main characteristic feature of
COPD, is associated with an infiltration of airway
by inflammatory cells and an increased expression of
cytokines, chemokines, enzymes, growth factors and
adhesion molecules [3]. Bronchoalveolar lavage (BAL) is
a useful procedure to sample the cellular and humoral
constituents of the lung microenvironment. Although
cellular changes in BAL fluid have been widely studied
in COPD patients [16], data about cellular composition
in lung cancer patients with COPD are lacking. There
are also not enough data comparing the cellular changes
in lung cancer and COPD.
A direct role of chronic inflammation in the pathoge-
nesis of lung cancer and its relation to the processes in
COPD is still not fully understood. Therefore, the aim of
our study was to evaluate the local and systemic chronic
inflammation by investigating the amount of neutrophils
and markers of their activity (ROS, NE, MPO) in peri-
pheral blood and BAL fluid of patients with lung cancer,
COPD and having both diseases simultaneously.
Results
Characteristics of subjects
The clinical characteristics of the study population are
described in Table 1. There were no significant age, BMI
differences between the groups. However, significantly
more lung cancer patients with COPD were current
smokers. Smoking intensity did not differ when comparedup Control group
ith COPD n = 55 COPD n = 40 Healthy individuals n = 33
50 (90.9) 36 (90.0) 24 (72.7)
5 (9.1) 4 (10.0) 9 (27.3)
64.5 ± 1.2 65.4 ± 1.2 62.6 ± 0.9
26.9 ± 0.5 28.4 ± 0.6 26.7 ± 0.6
0 0 11 (33.3)
7 (12.7) 19 (47.5) 10 (30.3)
48 (87.3) 21 (52.5) 12 (36.4)
30.0 (15–40) 33.0 (13–57) 22.0 (11–44)
40.0 (12–60) 39.5 (10–94) 32.0 (20–56)
56.7 ± 1.6§ 55.7 ± 2.3§ 106.6 ± 3.0
70.6 ± 1.1§ 74.0 ± 1.8§ 104.8 ± 0.4
ass index, COPD chronic obstructive pulmonary disease.
s groups.
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between COPD groups. There were significantly fewer
females in the COPD group compared with lung cancer
and healthy individual groups.
The clinical characteristics of the patients with lung
cancer are described in Table 2.
Cellular patterns of peripheral blood and BAL fluid
Table 3 shows the cellular patterns of peripheral blood
and BAL fluid from all the investigated groups. The
percentage and cell count of leucocytes, neutrophils and
monocytes in the peripheral blood were significantly
higher in patients with lung cancer with or without
COPD than in patients with COPD or healthy indivi-
duals (P < 0.05) (Table 3). Furthermore, the percentage
and cell count of leucocytes and neutrophils were
significantly higher in patients with COPD than healthy
individuals. The cell count of lymphocytes did not differ
between groups (P > 0.05). The neutrophil to lymphocyte
(N/L) ratio was significantly higher in lung cancer
patients with or without COPD compared to patients
with COPD or healthy individuals (Table 3). The N/L
ratio (3.28 ± 0.14 vs. 4.47 ± 0.03, P < 0.05) and neutrophil
cell count (5.61 ± 0.19 vs. 6.83 ± 0.52, P < 0.05) were
significantly higher in the lung cancer patients with poor
performance status 2–3, when compared to the patients
with performance status 0–1 as well as. There were no
significant differences in leucocyte, neutrophil, monocyte
cell counts and N/L ratio according to gender, stage and
histologic type of the disease (data not shown).
The percentage and cell count of neutrophils were
significantly higher in the patients with lung cancer withTable 2 Characteristics of patients with lung cancer at the
time of diagnosis
Variable Patients, No (%)
Histologic type:
Squamous cell carcinoma 42 (21.6)
Adenocarcinoma 86 (44.3)




Stage I 13 (6.7)
Stage II 9 (4.6)
Stage III 59 (30.4)




NSCLC non-small cell lung cancer, SCLC small cell lung cancer, NSCLC-NOS
non-small cell lung cancer not otherwise specified, ECOG Eastern Cooperative
Oncology Group.or without COPD than in healthy individuals but
significantly lower than in patients with COPD (P < 0.05).
The percentage and cell count of macrophages was
significantly higher in lung cancer groups and healthy
individuals, than in COPD group (P < 0.05).
Neutrophil ROS production in vitro
Neutrophils produced higher spontaneous ROS levels in
the groups of lung cancer patients with or without
COPD compared to the COPD patients or healthy
individuals (P < 0.05) (Figure 1). The spontaneous ROS
production in the lung cancer patients did not signifi-
cantly differ despite the coexistence of COPD. Sponta-
neous ROS production in neutrophils did not differ
between the male and female patients with lung cancer
(175.53 ± 2.12 MFI vs. 175.29 ± 3.78 MFI, P > 0.05). There
were no significant differences of spontaneous ROS pro-
duction in neutrophils among the major histologic types
of lung cancer: squamous cell carcinoma, adenocarcin-
oma, large cell carcinoma, non-small cell lung cancer not
otherwise specified and small cell carcinoma (166.53 ±
4.93 MFI, 176.50 ± 2.73 MFI, 172.29 ± 4.56 MFI, 182.47 ±
6.43 MFI, 180.53 ± 3.98 MFI, P > 0.05) as well as between
non-small cell lung cancer and small cell lung cancer
groups (174.67 ± 2.02 MFI vs. 180.53 ± 3.98 MFI, P > 0.05).
Additionally, spontaneous ROS production in neutrophils
was significantly higher in patients with advanced lung
cancer than in those with early lung cancer (183.66 ± 1.78
MFI vs. 145.91 ± 2.67 MFI, P < 0.001) and in the lung can-
cer patients with poor performance status 2–3 compared
with those with performance status 0–1 (209.10 ± 4.93
MFI vs. 169.37 ± 1.52 MFI, P < 0.001). Furthermore, the
patients with early lung cancer had a significantly higher
spontaneous ROS production in neutrophils than the
patients with COPD (P < 0.01). There were no significant
differences of spontaneous ROS production in neutrophils
in lung cancer groups among never smokers, former and
current smokers (174.75 ± 4.93 MFI, 181.00 ± 5.65 MFI,
174.33 ± 2.19 MFI, P > 0.05). Additionally, spontaneous
ROS production was found to be higher in lung cancer
patients with or without COPD, who have never smoked,
when comparing to current smokers with COPD
(172.86 ± 5.26 and 179.25 ± 3.68 vs. 64.29 ± 1.17, P < 0.001).
Different concentrations of PMA (0.3-30 nM) stimulated
ROS production in neutrophils in all studied groups
(Figure 1). An obvious increase of ROS production in
neutrophils was detected after stimulation with 0,3 nM of
PMA in lung cancer patients (with and without COPD),
and with 10 nM in COPD group (P < 0.05). But the most
significant increase of ROS production in all studied
groups was observed in neutrophils stimulated with
30 nM PMA. There were no correlations between sponta-
neous ROS production in neutrophils and age, BMI and
smoking intensity in study groups (data not shown).
Table 3 Total and separate cell percentage and counts in peripherial blood and BAL fluid
Variable Lung cancer group Control group
Without COPD With COPD COPD Healthy individuals
Peripheral blood cells, mean ± SEM:
Leukocytes, x109l 8.57 ± 0.25*§ 8.71 ± 0.48*§ 5.81 ± 0.13* 5.35 ± 0.17
Neutrophils, % 65.34 ± 0.85*§ 67.45 ± 1.43*§ 61.77 ± 1.18* 56.92 ± 1.65
Neutrophils, x109l 5.72 ± 0.22*§ 5.96 ± 0.39*§ 4.35 ± 0.22* 3.70 ± 0.25
Lymphocytes, % 23.01 ± 0.79*§ 21.11 ± 1.21*§ 25.93 ± 0.99* 31.64 ± 1.45
Lymphocytes, x109l 1.88 ± 0.06 1.84 ± 0.10 1.78 ± 0.09 1.99 ± 0.09
Monocytes, % 8.60 ± 0.30*§ 8.10 ± 0.49*§ 6.82 ± 0.29 6.26 ± 0.42
Monocytes, x109l 0.87 ± 0.09*§ 0.88 ± 0.17*§ 0.46 ± 0.03 0.40 ± 0.03
Neutrophil/lymphocyte ratio, median (range) 2.92(0.93–13.42)*§ 3.08(1.18–8.84)* § 2.35(1.13–4.25)§ 1.86(1.16–3.21)
BAL fluid cells, mean ± SEM:
Neutrophils, % 8.01 ± 1.37*§ 7.94 ± 0.83*§ 14.10 ± 2.96* 1.29 ± 0.21
Neutrophils, x106/ml 0.39 ± 0.12*§ 0.41 ± 0.15*§ 0.54 ± 0.22* 0.08 ± 0.05
Macrophages, % 73.59 ± 1.51§ 72.89 ± 1.71§ 65.50 ± 3.19* 74.40 ± 1.77
Macrophages, x106/ml 3.24 ± 0.20§ 3.15 ± 0.30§ 2.95 ± 0.65* 3.21 ± 0.51
Lymphocytes, % 18.21 ± 1.02 18.81 ± 1.48 19.99 ± 1.80 21.97 ± 1.62
Lymphocytes, x106/ml 0.87 ± 0.34 1.03 ± 0.37 1.11 ± 0.53 0.63 ± 0.26
Eosinophils, % 0.29 ± 0.04 0.36 ± 0.06 0.41 ± 0.15 0.34 ± 0.11
Eosinophils, x106/ml 0.02 ± 0.01 0.01 ± 0.01 0.03 ± 0.01 0.02 ± 0.01
Data are expressed as mean ± SEM. *P < 0.05 when compared with healthy individuals; §P < 0.05 when compared to COPD group.
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Serum and BAL fluid levels of both NE and MPO were
significantly higher in patients with lung cancer than in
patients with COPD or healthy individuals (P < 0.05)
(Figure 2). However, serum and BAL fluid NE and MPO
levels did not significantly differ in lung cancer groups
(with and without COPD) (P > 0.05). We did not find
any significant differences of NE and MPO levels in
serum and BAL between the male and female patients
with lung cancer (NE serum 518.64 ± 10.38 ng/mL vs.
489.22 ± 15.17 ng/mL, NE BAL fluid 297.34 ± 9.88 ng/mL
vs. 327.77 ± 18.79 ng/mL, MPO serum 297.56 ± 3.22 ng/mL
vs. 301.54 ± 15.80 ng/mL, MPO BAL fluid 111.69 ±
13.64 ng/mL vs. 112.83 ± 10.76 ng/mL, P > 0.05). There
were no significant differences of NE and MPO levels in
serum and BAL fluid between the non-small cell lung can-
cer and small cell lung cancer (NE serum 512.19 ±
8.99 ng/mL vs. 537.72 ± 11.97 ng/mL, NE BAL fluid
316.53 ± 8.43 ng/mL vs. 332.65 ± 25.03 ng/mL, MPO
serum 298.35 ± 13.16 ng/mL vs. 305.31 ± 17.32 ng/mL,
MPO BAL fluid 114.09 ± 14.08 ng/mL vs. 130.83 ±
10.91 ng/mL, P > 0.05) as well as among various histo-
logical types of cancer (data not shown). However, serum
NE and MPO levels were significantly higher in patients
with advanced lung cancer than in those with early lung
cancer (P < 0.05) (Figure 2). Furthermore, patients with
early lung cancer had a significantly higher NE levels than
patients with COPD (P < 0.01).There were no significant
differences of NE and MPO levels in serum and BAL fluidin lung cancer patients with performance status 0–1 when
comparing to patients with performance status 2–3
(NE serum 509.51 ± 8.76 ng/mL vs. 528.01 ± 18.45 ng/mL,
NE BAL fluid 314.38 ± 8.29 ng/mL vs. 338.21 ±
25.08 ng/mL, MPO serum 297.13 ± 13.00 ng/mL vs.
300.85 ± 18.03 ng/mL, MPO BAL fluid 112.94 ± 14.14
ng/mL vs. 121.72 ± 11.92 ng/mL, P > 0.05). There were no
differences of NE and MPO levels in lung cancer groups
(with or without COPD) among subjects that have never
smoked, former and current smokers (P > 0.05). Addition-
ally, NE and MPO levels in serum and BAL fluid were
found to be significantly higher in the lung cancer
patients, who have never smoked compared with the cur-
rent smokers with COPD (NE serum 480.11 ± 19.05 vs.
132.51 ± 18.72, MPO serum 286.96 ± 9.94 vs. 183.42 ±
11.95, MPO BAL fluid 103.65 ± 5.19 vs. 68.43 ± 7.59,
P < 0.05). Correlations between NE, MPO levels and spon-
taneous ROS production in the peripheral blood neu-
trophils in patients with lung cancer are presented in
Table 4. No correlations were found between serum and
BAL fluid NE, MPO levels and age, BMI, smoking inten-
sity in the investigated groups (data not shown).
Discussion
The goal of this study was to investigate local and
systemic neutrophilic inflammation in patients with lung
cancer and COPD considering the common inflam-
matory signaling pathway in both diseases. It is known















Figure 1 A histogram representing changes in ROS production in the neutrophils of peripheral blood of study patients after
stimulation with different concentrations of PMA. Data are presented as mean fluorescence intensity (MFI) ± SEM. *P < 0.05, when compared
with COPD and healthy individuals groups; §P < 0.05, when compared with healthy individuals. The representative dot plot of neurophil
population isolated from peripheral blood of healthy individuals (A), patients with COPD (B), patients with lung cancer/COPD (C) and patients
with lung cancer (D) stimulated upon 30 nM of Phorbol 12-myristate 13-acetate (PMA). Side light scater (SSC) represents the granularity,
complexity of the cells; FSC – forward light scatter (FSC) represents cell size; dihydrorhodamine-123 (DHR-123) a green fluorescent compound
showing H2O2 intensity in neutrophils.
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comparing chronic inflammatory processes when there
is coexistence of lung cancer and COPD. It is known
that COPD is a major independent risk factor for lung
cancer among smokers and about 50-90% of patients
with lung cancer also have COPD [17]. A mechanism,
explaining why smokers with COPD have an increased
risk for lung cancer when compared to smokers without
COPD, is still not clear. Furthermore, it is still not
known why some patients with COPD get lung cancer
and some patients don't. In order to understand the
inflammatory mechanisms and associations between lung
cancer and COPD we aimed to analyze the patterns oflocal (BAL fluid) and systemic (peripheral blood) chronic
neutrophilic inflammation in lung cancer and COPD.
Our results are consistent with the findings of pre-
vious reviews, showing that the count of neutrophils in
peripherial blood was higher in lung cancer patients [18]
as well as in patients with COPD [19] when compared
to healthy individuals. To our knowledge such data
comparing neutrophil cell count and N/L ratio in lung
cancer patients, patients with COPD and both diseases
in coexistence are presented for the first time. Recent
studies have shown that the N/L ratio has a significant
prognostic value for chronic conditions such as hyper-

































































Figure 2 NE and MPO levels (ng/mL) in serum and BAL fluid in patients with advanced and early stage lung cancer, patients with lung
cancer/COPD, patients with COPD and healthy individuals. Data are presented as mean ± SEM. *P < 0.05, when compared with COPD and
healthy individuals; §P < 0.05, when compared with healthy individuals.
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neutrophil cells count and N/L ratio in peripheral blood
in patients with lung cancer compared with COPD
patients, but did not find significant difference between
the groups of lung cancer patients with COPD and with-
out COPD. Furthermore, N/L ratio was significantly
higher in patients with COPD than in healthy subjects.
The development of chronic systemic neutrophilia in
cancer, as well as in COPD, has not been fully under-
stood. There are some hypotheses explaining pathoge-
netic mechanisms, which are responsible for the increased
neutrophil count in the peripheral blood. One of them,Table 4 Correlation between serum and BAL fluid NE,
MPO levels and spontaneous ROS production in
peripheral blood neutrophils in patients with lung cancer
Spontaneous ROS production
r p
NE serum 0.396 0.007
NE BAL fluid 0.461 0.004
MPO serum 0.428 0.005
MPO BAL fluid 0.382 0.007
NE neutrophil elastase, MPO myeloperoxidase, BAL fluid bronchoalveolar
lavage fluid.states that increased neutrophil count in peripheral blood
in case of COPD can be influenced by the airway inflam-
mation. This enhanced neutrophil influx to the airways
may stimulate the activation of inflammatory markers,
which on the other hand activate the neutrophils, cause
an increase in their vitality and migration to the lung
tissue due to chemoattractants [25]. The other hypothesis,
suggests that an enhanced expression of granulocyte-
macrophage colony-stimulating factor and IL-6 in patients
with COPD [19,26] plays and important role, as these
mediators stimulate neutrophil release from the bone
marrow, causing the increased neutrophil count in the
peripheral blood. The same mechanisms can be respon-
sible for the increased numbers of neutrophils and N/L
ratio in lung cancer as well. However, there is additional
mechanism that could contribute to the increase in
neutrophil count. Cancer cells produce granulocyte
colony-stimulating factor, which directly stimulates bone
marrow to release neutrophils [27]. Because of these
mechanisms, lung cancer patients have higher neutrophil
count and more pronounced systemic chronic inflamma-
tion than patients with COPD.
There are limited data comparing local inflammation
in lung cancer patients and COPD. Analysis of BAL fluid
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immune processes in the airway microenvironment. In
agreement with the data from other studies, our results
revealed that percentage and cell count of neutrophils
were significantly higher in lung cancer patients [28,29]
and COPD patients [16] compared with healthy subjects.
In contrast to neutrophilia in peripheral blood, percen-
tage of neutrophils in BAL fluid was significantly lower
and percentage of macrophages was significantly higher
in lung cancer patients compared with COPD patients.
Furthermore, we observed that in lung cancer patients,
when compared with COPD patients, not only the count
of macrophages in BAL fluid was increased, percentage
and cell count of monocytes in peripheral blood were
also higher. Lung cancer cells generate chemotactic
factors and chemokine ligand for circulating monocytes,
which are recruited into the lungs, where they differenti-
ate into the macrophages [30]. It is known that immune
cells, including macrophages, infiltrate the tumor stroma
[2,31]. It is well know that monocyte-lineage cells
including macrophages also play an important role in
the pathogenesis of COPD [3]. A plausible explanation
for the increased count of macrophages in BAL fluid of
patients with lung cancer is that tumor promotes
migration of monocytes and their differentiation into the
macrophages. This confirms the fact, that macrophages
play central role in the immune response to lung cancer.
We observed that mean serum and BAL fluid levels of
NE and MPO were significantly higher in patients with
lung cancer (with or without COPD) compared with
COPD patients and healthy subjects. Neutrophil elastase
and MPO are important markers of neutrophil activation
and neutrophilic inflammation [9,10]. Some studies have
identified increased NE and MPO levels in patients with
COPD [14] and healthy smokers [10]. The role of NE and
MPO in chronic lung inflammation and association with
lung cancer development has been characterized in cell
line and animal models [11-13,32]. Nevertheless, there are
no clear data comparing the importance of NE and MPO
in lung cancer and COPD. Although we demonstrated
that neutrophil cell count and percentage in BAL fluid
were lower in lung cancer groups compared with COPD
patients, NE and MPO levels in BAL fluid were signifi-
cantly higher in lung cancer groups than in COPD group.
Thus, our findings let us hypothesize that in patients with
lung cancer neutrophils appear in a more activated state
through the production of NE, MPO than in patients with
COPD. Furthermore, there are some data showing that
NE and MPO is expressed not only in neutrophils but also
in monocyte-derived macrophages [33].
It is generally accepted that oxidative stress, which is
promoted by cigarette smoke, may be involved in cancer
development [2,5]. The literature is full of data on the
increased oxidative stress in patients with COPD [3,7].However it is still little known about ROS production in
lung cancer patients with COPD and data comparing
lung cancer with COPD are lacking. In the present study
we demonstrated that spontaneous ROS production in
peripheral blood neutrophils was higher in both lung
cancer groups (lung cancer and lung cancer with COPD)
than in patients with COPD, but there were no differences
between lung cancer patients with COPD or without
COPD. Heijink and colleagues suggested that chemical
factor like cigarette smoke may influence a more intensive
ROS production in COPD and healthy individuals [34]. As
a chemical factor which causes neutrophil activation we
used a PMA. Our study showed that PMA induced
intensive ROS production not only in patients with COPD
and healthy individuals but in lung cancer patient groups
(with and without COPD) as well. Our results revealed
that activated neutrophils after stimulation with PMA
produced more ROS in lung cancer patients (with and
without COPD) compared with COPD patients. It means
that chemical factors cause enhanced inflammation in
lung cancer. In addition, we provided evidence that intra-
cellular ROS was increased in peripheral blood neutro-
phils of lung cancer patients which positively correlated
with levels of both inflammatory markers (NE, MPO).
Such correlation supports the hypothesis that intensive
chronic neutrophilic inflammation promotes more inten-
sive ROS production in lung cancer compared to COPD.
We also investigated levels of NE, MPO and ROS
production in the patients with different stage of lung
cancer (early vs. advanced). Our data demonstrated that
patients with advanced lung cancer had significantly
higher serum NE, MPO levels and more intensive ROS
production in peripheral neutrophils than patients with
early stage lung cancer. These results are consistent with
the results reported in other studies [11], presenting
additional evidence of the importance of chronic neu-
trophilic inflammation in lung cancer progression [2].
Furthermore, our findings of higher systemical NE, MPO
and ROS production in patients with early lung cancer
compared with COPD patients further support the fact,
that chronic inflammation can be more pronounced in
lung cancer than COPD.
Additional studies have demonstrated that smoking
stimulates not only local but also systemic inflammation
[6,16]. However, the data on the influence of smoking
itself on chronic neutrophilic inflammation in lung cancer
patients with coexisting COPD are scarce. The data are
contradictory, some researches have shown that cigarette
smoke is strongly associated with the increased inflamma-
tion of airways, proved by the exhaled breath condensate
in lung cancer patients [35]. Other study failed to prove
these associations in lung cancer patients [36]. There is
evidence that cigarette smoking plays an important role as
the starting point of chronic inflammation [6] but has
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However, our results indicate that in patients with lung
cancer local and systemic inflammation was increased
independent of smoking and not only cigarette smoking
but also other factors play a significant role in promotion
of chronic inflammation in lung cancer.
Conclusions
We observed that individuals with lung cancer (with or
without COPD) had more pronounced local and systemic
neutrophilic inflammation in comparison with patients
with COPD and healthy subjects. These data permit a
suggestion that neutrophilic chronic inflammation has a
significant role in lung cancer pathogenesis and is more




We investigated 267 subjects: 139 patients with lung
cancer, 55 lung cancer patients with stable moderate to
severe COPD, 40 patients with stable moderate to severe
COPD and 33 healthy individuals at the Hospital of
Lithuanian University of Health Sciences Kaunas Clinics
from 2009 April to 2012 May. All patients met following
criteria: did not use inhaled or systemic steroids at least
1 month before the study and had no clinical or radio-
logical evidence of infection. Subjects were excluded if
they had a history of another malignancy or other
diseases associated with systemic inflammation, such as
rheumatoid arthritis, inflammatory bowel disease or
connective tissue disorders. All lung cancer patients had
histologically confirmed disease according to the WHO
classification. The clinical stage, tumor type, and perfor-
mance status (according to Eastern Cooperative Oncology
Group (ECOG)) [37] of patients with lung cancer were
recorded at the time of diagnosis, before administering
anti-cancer therapy. Lung cancer stage was determined
according to the TNM Classification of Malignant Tumors,
the Seventh Edition [38]. Patients with lung cancer were
divided into two groups according to the stage of disease:
early lung cancer – patients with stage I-II cancer, and
advanced lung cancer – patients with stage III-IV cancer.
COPD was diagnosed according to the criteria of the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) [39]. At the time of evaluation, COPD patients
were clinically stable (no exacerbations during the previous
2 months). All COPD patients were screened for deficiency
of alpha-1 antitrypsin (AAT) by quantitative ELISA test
(Eurodiagnosta, Sweden). Peripheral venous blood samples
and bronchoscopy with BAL processing were obtained
before administering anti-cancer therapy.
Study subjects according to their smoking status were
divided into 3 categories: current smokers – smokingpersons, having more than 10 pack-years smoking his-
tory; former smokers – individuals, having more than
10 pack-years smoking history, who had ceased smoking
more than 2 years before the study; and never smokers –
individuals who have never smoked [16]. Smoking history
was calculated in pack-years as the product of tobacco use
(in years) and the average number of cigarettes smoked
per day/20 (years × cig. per day/20).
Body mass index (BMI) was calculated as measured
weight (kg) divided by the square of measured height (m)2.
Kaunas Regional Ethics Committee for Biomedical
Research approved the study and written informed consent
was received from all participants.Lung function testing
Lung function was tested using a pneumotachometric
spirometer “CustovitM” (Custo Med, Germany) with
subjects in the sitting position. The highest value of
forced expiratory volume in 1 second (FEV1) and forced
vital capacity (FVC) from at least two technically satisfac-
tory maneuvers differing by less than 5% were recorded.
Predicted values were obtained from Quanjer et al. [40].
The subjects had to avoid the use of short-acting β2-
agonists at least 8 h prior the test.BAL processing
BAL was performed in 76 patients with lung cancer, 43
patients with lung cancer and COPD, 37 patients with
COPD and 28 healthy individuals, using fiberoptic bron-
choscopy according to ERS guidelines for measurement
of a cellular components and recommendations for
standardization of BAL [41]. No serious complications
occurred during or after the bronchoscopies. Before
BAL procedure, the local upper airways anesthesia with
5 mL of 2% lidocaine (Grindex, Latvia) was performed.
All bronchoscopy examinations were scheduled in the
morning. In the group of patients with lung cancer BAL
samples were taken during the diagnostic procedure
from the lobe affected by the tumor (in cases with per-
ipheral mass) or from the lobe adjacent to the affected
lobe (in cases with a central mass) [28]. In patients with
COPD and healthy individuals BAL samples were taken
from the middle lobe [41]. The bronchoscope (Olympus,
USA) was wedged into the segmental bronchus and
20 mL × 7, a total of 140 mL, of sterile saline solution
(0.9% NaCl) was infused. Fluid was gently aspirated
immediately after the infusion and was collected into a
sterile container. The fluid was immediately filtered
using 40 μm cell stainer (Becton Dickinson, USA) and
centrifuged at 4°C for 10 min. Supernatants were remo-
ved and frozen at −70°C for further ELISA analysis. BAL
cytospins were prepared using a cytocentrifuge (Shandon
Southern Instruments, USA).
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Prepared cytospins from the BAL fluid were stained
using the May-Grünwald/Giemsa method for differential
cell counts. Then 400 nonsquamous cells were counted
per slide. The type of cell was identified using standard
morphological criteria. Percentage (percentage of total
nonsquamous cells) and absolute values (106/mL) of all
cell counts were recorded.
Serum processing
Peripherial blood from all tested patients was collected
into sterile tubes without additives (2×5 mL) and stored
at room temperature for the surface clot formation
(about 30 min). Then tubes were centrifuged at 1000 × g
for 10 min at room temperature. From the upper layer
of the sample the serum was vacuumed into sterile cold-
resistant Eppendorf tubes and stored at −70°C for
further ELISA analysis.
Detection of serum and BAL fluid NE and MPO
NE and MPO levels in serum and BAL fluid were measured
by enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s instructions (IBL International, USA
and Immundiagnostik AG, Germany, respectively). The
minimum detectable dose was 0.16 ng/mL for NE and
0.014 ng/mL for MPO. The concentration of NE and MPO
in the samples was determined by comparing the optical
density values of the samples to the standard curve.
The peripheral blood cell analysis was performed on
an automated haematology analyser (Sysmex XE-5000,
Japan). Neutrophil to lymphocyte ratio was calculated as
the absolute neutrophil count divided by absolute lym-
phocyte count.
Peripheral blood collection and isolation of neutrophils
Peripheral blood samples for neutrophil isolation were
collected into sterile vacutainers with ethylene diamine
tetraacetic acid (EDTA). Neutrophils were isolated by
high density gradient centrifugation. The whole blood
was layered on Ficoll-Paque PLUS (GE Healthcare,
Finland) and centrifuged at 1000 g for 30 min at room
temperature. Neutrophil population was separated by
hypotonic lysis of erythrocytes. Isolated neutrophils
were diluted in cell culture RPMI 1640 media (Biological
Industries, Israel), at a final concentration of 2 × 106/ml.
The viability of neutrophils was checked by flow cytome-
try and it always was > 95%.
In vitro ROS production in neutrophils
ROS production in neutrophils was induced by chemical
(phorbol 12-myristate 13-acetate (PMA), 0.1, 0.3, 1, 3, 10,
30 nM) factor in sterile 96-well microplates (Falcon). For
the detection of generated ROS, a nonfluorescent dye,
dihydrorhodamine-123 (DHR-123, final concentration,750 ng/mL; Invitrogen, USA), was added. DHR-123
interacts with intracellular ROS and is oxidized to
green-fluorescent fhodamine 123 (catalysed by cellular
myeloperoxidase, MPO). Plates filled with different
concentrations of PMA and neutrophil suspension were
incubated for 45 min. at 37°C, 5% CO2. The relative
amount of generated ROS was measured by flow cytometry
determining the mean fluorescence intensity in neutrophil
population (excitation wavelength, 488 nm).
Flow cytometric analysis
Flow cytometric measurements were performed with a
FACSCalibur cytometer (Becton Dickinson, USA). For
each determination at least 104 events were acquired.
Characteristic (size and granularity/complexity) properties
of neutrophils served to determine the purity of cellular
suspensions and to monitor morphological changes after
incubation and stimulation with tested substances. The
total number of viable neutrophils was quantified and iden-
tified by adding propidium iodide (2 mg/mL, Calbiochem,
Germany), which stains deoxyribonucleic acid of dead cells.
Data were analyzed with the software CellQuest.
Statistical data analysis
Statistical analysis of data was performed using the statis-
tical SPSS for Windows 20.0 software package. Data are
presented as means ± standard error of the mean and me-
dian with data range. The categorical data were analyzed
using of the chi-square (χ2) test. For comparisons of data
in more than two groups we used ANOVA or Kruskal-
Wallis tests and in two groups - the Student t test or
Mann–Whitney test for parametrically or nonparametri-
cally distributed data respectively. The association between
the levels of inflammation markers and clinicopathological
characteristics was measured by the Pearson correlation
coefficient.
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